Decentralised & hybrid clinical trials
Patient focused research for better outcomes
In-Home Services
Bring your clinical trial directly to patients when and where it's convenient for them to reduce patient burden and increase recruitment and retention.
With the rising cost and time to bring new drugs to market and more recently the pandemic outbreak, the demand for decentralised and hybrid trials has risen. These alternative trial models can range in shape and form to include digital health technologies, in-home clinical visits and remote monitoring.
Practical considerations in transitioning to hybrid or decentralised clinical trials
Everyone is talking about decentralised clinical trials. But how can we leverage what we learnt during 2020 and move forward in a more systematic way to deploy this approach with maximum efficiency and optimum results?
Read the whitepaperBiopharma perspective: The promise of decentralised models and diversity in clinical trials
ICON invited senior biopharma executives to discuss how decentralised and hybrid clinical trial models can provide increased resilience and to share how their respective organisations are currently or likely to address diversity and inclusion in clinical trials going forward. This summary report outlines how these executives see the opportunity in the developments of 2020, paving the way for continuous improvements into the future.
Read the summary reportPatient insight - decentralised & hybrid clinical trials
Engaging patients more fully and making sure decentralised clinical trials are easing rather increasing burden is going to be crucial to using these models in the longer term. Early in 2021, ICON conducted a survey to compare it to one conducted in 2019 to see if the COVID-19 outbreak had changed the sentiment and increased interest in participating in clinical trials remotely.
Read the survey resultsIn-home services in decentralised clinical trials
Bringing clinical trial visits to patients in their homes decreases burden and leads to higher enrollment rates. Explore the benefits and solutions to overcome perceived barriers so that you can provide this as an option on your next trial.
Read the whitepaperAdvancing digital endpoints
Although mHealth devices and sensors are continuing to evolve, and it is now possible to capture a vast array of physiological data, the operationalisation of digital trials is not without challenges. Navigate the shift from traditional trial models to agile, patient-centric processes driven by digital health technologies.
Read the whitepaperAgile clinical monitoring
During COVID-19 the levels of remote monitoring increased due to site closures and safety reasons. Now is the time to learn from that experience and review whether a hybrid model of remote monitoring and centralised monitoring is the way forward for some trials. Learn best practices in analysing and assessing risk in clinical monitoring and how to remain agile adapting to environmental conditions and therapeutic focus.
Read the whitepaperAccellacare In-Home Services
Bringing the trial to the patient:
- Webinar: In-home visits in clinical trials
- Factsheet: In-Home Services to reduce patient burden
- Case study: Expanding geographic reach in rare disease study
- Case study: Special populations and procedures for maternal and infant studies
mHealth & wearables
Understand how to implement wearable devices and harness digital endpoints in clinical trials:
- Webinar: The template for implementing a successful digital trial
- Factsheet: Wearables and digital endpoint validation
- Case study: Wearables and remote monitoring: Quantifying cough with sensor technology
- Case study: Conducting a trial in a community setting: The REACHES study
Decentralised and hybrid trials webinars
Regulatory considerations for technology in decentralised clinical trials
Understanding the regulatory and legal aspects behind the technology applied in decentralised clinical trials.
Decentralised and hybrid trials - engaging important stakeholders: Patients and investigators
ICON's E.B. McLindon speaks at Decentralized Clinical Trials digital week. Gain insights and perspectives on design studies, to improve patient engagement and meeting study endpoints.
Building resilience in pharma R&D by decentralising and digitising
The COVID-19 outbreak has driven the desire for more resilient clinical trials. The deployment of remote clinical monitoring is proving its value in helping to keep trials going at a time when site management is particularly challenging.
In-home visits in clinical trials
The FDA guidance on clinical trials during COVID-19 advised sponsors to evaluate alternative methods for safety assessments to protect patients, where necessary and feasible.
Decentralised and hybrid trials blogs
Real-time monitoring of the digital patient in clinical trials
The collection of real-time data in a home setting can give sponsors and trial managers greater visibility and assurance around GCP and protocol compliance.
Decentralised and hybrid trials videos
Receive more insights on decentralised & hybrid clinical trials from ICON
Please visit ICON's Preference Centre and select 'Decentralised & Hybrid Clinical Trials' under 'Patient Centricity' to receive new insights on decentralised & hybrid clinical trials.
Receive new insightsDecentralised and hybrid trials media contributions
Trial blazing
Harpreet Gill, Vice President, Decentralised Clinical Trials at ICON reflects on the progress that has been made in decentralised and hybrid clinical trials in the last number of years in this article in PharmaTimes.
Boon and bane: dodging participant burden in decentralised clinical trials
As DCT adoption increases, Harpreet Gill looks at how sponsors and CROs must mind the risk of adding patient burden while designing decentralised trials.
Providing support throughout the patient journey
Concierge services are critical to helping patients navigate technology and other logistics in a decentralised clinical trial. Laney Preheim outlines how they can best be implemented.
Tech advances making decentralised trial growth possible
Dr. Isaac R. Rodriguez-Chavez discusses the technology advancements that are making decentralised trial growth possible.
Decentralised clinical trial transformations are ‘here to stay’
Dr. Isaac R. Rodriguez-Chavez discusses the various factors behind the DCT format's rapid rise and likely longevity in the drug development arena.
The surge of digital health technologies modernising clinical research
Dr. Isaac R. Rodriguez-Chavez outlines the key considerations when developing digital health technologies.
The innovative 'digiverse' that's propelling transformative decentralised clinical trials
Dr. Isaac R. Rodriguez-Chavez offers his insights on the use of innovative digital health technologies and digital ecosystems to support decentralised clinical trials.
Identifying integrated digital platforms designed for a decentralised future
Matt Harrington explores how the use of digital platforms and associated services can contribute to more adaptable, accessible and efficient clinical trials.
Decentralised clinical trials: mapping patient pathways with a focus on patient-centricity
Emily Mitchell discusses the importance of considering the target patient population when designing and deploying a decentralised clinical trial.
Evolution of clinical trial data calls for evolved response
Emily Mitchell and Kathleen Mandziuk discuss how study data has progressed in recent years and how trial teams can keep up effectively with proper data management.
JPM 2022: Decentralised trials, broader service offerings and novel drugs key trends in the CRO space
A snapshot from the J.P. Morgan Healthcare Conference 2022.
In-Home Services: A patient-centric approach to improving recruitment and retention in clinical trials
An interview with Jodie Huddleston on the use of hybrid and decentralised models as viable solutions in clinical trial design.
Capture, curate, consume: The three Cs of managing data in decentralised and hybrid clinical trials
Emily Mitchell and Christina Dinger run through some of the most important elements of collating and organising data during clinical trials.
Decentralised trials dramatically transforming clinical research: ICON
Isaac Rodriguez-Chavez discusses the impact decentralised trials have had on the industry, and how that transformation is likely to continue.
Decentralised Clinical Trials and Real World Evidence
In this video interview, Kim Boericke, President, Commercialization and Outcomes Services, discusses what is driving a great focus and intensity on outcomes in clinical trials, trends coming in 2022, and the use of real-world data and the rare disease space.
Operationalising decentralised clinical trials
In this article, our experts discuss the challenges and change management approaches that ICON faced during the COVID-19 pandemic, and how we overcame them through the use of decentralised and hybrid clinical trials.
Video series: The 3 "Cs" of the data journey
This three part video series examines some of the factors that should be considered to ensure that clinical trial data captured via wearable devices, is monitored expeditiously and effectively.
The waterfall effect of digital health technology on unifying healthcare and clinical research
Isaac R Rodriguez-Chavez contributes to the DPHARM Autumn 2021 newsletter, discussing the use of digital health to maximise efficiencies in decentralised clinical trials.
CROs: Yesterday, today and tomorrow
ICON's Kent Thoelke discusses today’s key trends for CROs, including the increasing adoption of decentralised clinical trials (DCTs) and the growing use of remote monitoring to collect data.
Ensuring better patient outcomes through decentralised trials
The research industry has changed in the past year, and decentralised models are helping to improve patient outcomes and bring treatments to market faster (page 12).
Practical considerations when deploying a decentralised or hybrid clinical trial
A discussion around the key components of decentralised trials and steps of deployment.
Pragmatic steps to using mobile technology in clinical trials
Wearables and other mobile technologies are increasingly recognised as drivers of democratisation and diversification in clinical trials.
Will COVID-19 bring lasting change in clinical trial practices?
COVID-19 may be the inflection point that tips clinical trial practices into the digital age.
eBook: Digital acceleration in clinical trials
Digital health has been a hot topic for many years, but it has taken the pandemic to really highlight its value across many areas of the pharma and biotech industries.
Decentralised, hybrid or traditional
Choosing the best option for your clinical trial.
Wearables in virtual clinical trials
Wearables are improving the clinical trial experience for patients and satisfying the need to collect data for real-world use studies.
Pfizer COVID vaccine trial proved remote monitoring and other innovations work
Starting clinical trials in weeks, as opposed to months, should be possible post-pandemic.
Bringing the trial to the patient
Reducing the burden that clinical trial participation places on patients can help to keep patients engaged in clinical research.
Mapping the patient journey and minding the gap
Seven steps to closing the gap between rhetoric and reality in patient-centricity.
Patient centricity
Exploring the patient perspective from different angles.
Thwarting cyber attacks
Steps to implement security into mHealth development.
The power of patients
Patient engagement is permeating all spheres of the healthcare ecosystem.
Decentralising research
Revolutionising clinical trials with wearables and digital endpoints.
Listening to the patient for better outcomes
Project teams need to be challenged constantly to justify the study procedures and eligibility criteria they are proposing.
True patient-focused research through decentralised and hybrid trials
How can pharma improve the patient centricity of its trials during COVID-19 and beyond?
ICON's solutions in decentralised and hybrid clinical trials
Decentralised and hybrid trials bring a wide range of benefits to the patient and the sponsor. Find out more about the range of decentralised and hybrid trials services available from ICON.
Read more about ICON's services